In Wuhan, China, the first COVID-19 patient with MM was successfully treated with tocilizumab. MM is a cancer of plasma cells, which are a type of white blood cells that generate antibodies to help the body fight infections. Several studies have shown that tocilizumab, a drug that inhibits Interleukin-6 (IL-6), is able to effectively calm the strong inflammatory response in COVID-19 patients.

• History of patient diagnosed with COVID-19 and MM
• Methods that were used to treat COVID-19 patient with MM
• Results of the first COVID-19 patient with MM
• Discussion of the first COVID-19 patient with MM